{"organizations": [], "uuid": "5c7ca9e1d9837926f7d42b9befe75ec918d909ed", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-zynerba-pharmaceuticals-says-zyn00/brief-zynerba-pharmaceuticals-says-zyn002-was-shown-to-be-well-tolerated-through-12-months-of-treatment-in-star-2-study-idUSFWN1S20R0", "country": "US", "domain_rank": 408, "title": "BRIEF-Zynerba Pharmaceuticals Says ZYN002 Was Shown To Be Well Tolerated Through 12 Months Of Treatment In Star 2 Study", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-25T14:15:00.000+03:00", "replies_count": 0, "uuid": "5c7ca9e1d9837926f7d42b9befe75ec918d909ed"}, "author": "", "url": "https://www.reuters.com/article/brief-zynerba-pharmaceuticals-says-zyn00/brief-zynerba-pharmaceuticals-says-zyn002-was-shown-to-be-well-tolerated-through-12-months-of-treatment-in-star-2-study-idUSFWN1S20R0", "ord_in_thread": 0, "title": "BRIEF-Zynerba Pharmaceuticals Says ZYN002 Was Shown To Be Well Tolerated Through 12 Months Of Treatment In Star 2 Study", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-zynerba pharmaceuticals", "sentiment": "negative"}, {"name": "well tolerated through 12 months of treatment in star", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "min read    zynerba pharmaceuticals inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 25 (Reuters) - Zynerba Pharmaceuticals Inc:\n* ZYNERBA PHARMACEUTICALS SAYS ZYN002 WAS SHOWN TO BE WELL TOLERATED THROUGH 12 MONTHS OF TREATMENT IN STAR 2\n* ZYNERBA PHARMACEUTICALS - LOOK FORWARD TO INITIATING A PHASE 2B STUDY IN ADULT REFRACTORY FOCAL SEIZURES IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-04-25T14:15:00.000+03:00", "crawled": "2018-04-25T14:30:49.010+03:00", "highlightTitle": ""}